📊 MNOV Key Takeaways
Is Medicinova Inc. (MNOV) a Good Investment?
MedicineNova is experiencing severe operational deterioration with revenue collapsing 59% YoY to just $187K while burning $3.5M annually in operating losses. While the company maintains a strong cash position ($27.3M) and zero debt, the dramatic revenue decline combined with minimal capital investment and zero insider activity suggests fundamental business challenges that exceed the financial cushion provided by cash reserves.
MediciNova’s fundamentals reflect minimal and declining revenue with deeply negative margins, ROA/ROE, and sustained operating losses, indicating no near-term path to profitability. While the balance sheet is clean with ample cash, no debt, and negligible capex needs, free cash flow is materially negative and growth quality is weak. Without clear, durable revenue traction, the risk profile outweighs the liquidity strength.
Why Buy Medicinova Inc. Stock? MNOV Key Strengths
- Strong cash position of $27.3M (63.9% of total assets) provides 7-8 years of runway at current burn rate
- Zero long-term debt with clean balance sheet and minimal liabilities ($3.3M)
- Excellent liquidity metrics (Current Ratio 9.09x, Quick Ratio 9.09x) eliminates near-term solvency risk
- Debt-free balance sheet with ~$30.8M cash runway
- High liquidity (8.16x current/quick) and low liabilities
- Capital-light model with negligible capex
MNOV Stock Risks: Medicinova Inc. Investment Risks
- Revenue declining 59% YoY to $187K indicates fundamental business deterioration or loss of major revenue source
- Massive operating losses with -1516.6% operating margin and negative cash flow of -$3.5M annually
- Minimal capital expenditure of only $10.8K suggests negligible R&D investment and limited pipeline advancement
- Zero Form 4 insider filings in 90 days indicates lack of management confidence in company trajectory
- For pharmaceutical company, this revenue profile suggests failed commercialization or pipeline failure rather than clinical-stage development
- Persistent operating losses and negative free cash flow
- Revenue base is small and down 59% YoY
- Dependence on partnerships/financing and clinical milestones to reach profitability
Key Metrics to Watch
- Quarterly revenue trend stability - any reacceleration or further decline would be critical signal
- Operating cash burn rate relative to cash runway - timing of next funding need
- Clinical pipeline progress and FDA approval timeline for candidate programs
- insider transactions and management compensation changes - signal of confidence/distress
- Operating cash flow burn and cash runway
- Revenue from collaborations/grants and R&D expense trend
Medicinova Inc. (MNOV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.09x current ratio provides a solid financial cushion.
MNOV Profit Margin, ROE & Profitability Analysis
MNOV vs Healthcare Sector: How Medicinova Inc. Compares
How Medicinova Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Medicinova Inc. Stock Overvalued? MNOV Valuation Analysis 2026
Based on fundamental analysis, Medicinova Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Medicinova Inc. Balance Sheet: MNOV Debt, Cash & Liquidity
MNOV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Medicinova Inc.'s revenue has declined by 90% over the 5-year period, indicating business contraction. The most recent EPS of $-0.23 indicates the company is currently unprofitable.
MNOV Revenue Growth, EPS Growth & YoY Performance
MNOV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $187.0K | -$2.6M | $-0.05 |
| Q3 2025 | $123.3K | -$2.6M | $-0.06 |
| Q2 2025 | $134.6K | -$2.6M | $-0.05 |
| Q3 2024 | $1.0M | -$723.1K | $-0.01 |
| Q3 2023 | $1.0M | -$723.1K | $-0.01 |
| Q3 2022 | $37.5K | -$187.8K | $-0.07 |
| Q2 2022 | $4.0M | -$187.8K | $-0.08 |
| Q1 2022 | $4.0M | -$187.8K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Medicinova Inc. Dividends, Buybacks & Capital Allocation
MNOV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Medicinova Inc. (CIK: 0001226616)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MNOV
What is the AI rating for MNOV?
Medicinova Inc. (MNOV) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MNOV's key strengths?
Claude: Strong cash position of $27.3M (63.9% of total assets) provides 7-8 years of runway at current burn rate. Zero long-term debt with clean balance sheet and minimal liabilities ($3.3M). ChatGPT: Debt-free balance sheet with ~$30.8M cash runway. High liquidity (8.16x current/quick) and low liabilities.
What are the risks of investing in MNOV?
Claude: Revenue declining 59% YoY to $187K indicates fundamental business deterioration or loss of major revenue source. Massive operating losses with -1516.6% operating margin and negative cash flow of -$3.5M annually. ChatGPT: Persistent operating losses and negative free cash flow. Revenue base is small and down 59% YoY.
What is MNOV's revenue and growth?
Medicinova Inc. reported revenue of $187.0K.
Does MNOV pay dividends?
Medicinova Inc. does not currently pay dividends.
Where can I find MNOV SEC filings?
Official SEC filings for Medicinova Inc. (CIK: 0001226616) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MNOV's EPS?
Medicinova Inc. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MNOV a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Medicinova Inc. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MNOV stock overvalued or undervalued?
Valuation metrics for MNOV: ROE of -6.6% (sector avg: 15%), net margin of -1,383.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MNOV stock in 2026?
Our dual AI analysis gives Medicinova Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MNOV's free cash flow?
Medicinova Inc.'s operating cash flow is $-3.5M, with capital expenditures of $10.8K. FCF margin is -1,861.7%.
How does MNOV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,383.1% (avg: 12%), ROE -6.6% (avg: 15%), current ratio 9.09 (avg: 2).